Fosun Pharma: Approval obtained for the registration of Nitroglycerin Injection

Fosun Pharma announced on April 30th that its controlling subsidiary, Chongqing PharmaFriend Pharmaceutical Co., Ltd., has received approval for the drug registration application of sodium nitroprusside injection from the National Medical Products Administration. The approved indications for this drug include hypertensive crisis, such as hypertensive emergency, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension before and after surgery for pheochromocytoma, as well as for controlled hypotension during surgical anesthesia; acute heart failure, including acute pulmonary edema, and also for acute heart failure in the case of acute myocardial infarction or valvular insufficiency.